HORMONE SENSITIVE PROSTATE CANCER
Clinical trials for HORMONE SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for HORMONE SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on prostate cancer shows promise in early trial
Disease control OngoingThis phase 2 study tests a combination of hormone therapy, chemotherapy, and an immunotherapy drug (nivolumab) in men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively. The tr…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Xiao X. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo shows promise in delaying prostate cancer spread
Disease control OngoingThis phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug cocktail aims to stall prostate cancer in men with PTEN mutation
Disease control OngoingThis study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Prostate cancer study aims to restore testosterone after Long-Term therapy
Disease control OngoingThis study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Atish Choudhury, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New radioactive drug takes aim at Hard-to-Treat prostate cancer
Disease control OngoingThis study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New scan method could Fine-Tune prostate cancer therapy
Knowledge-focused OngoingThis study explores whether special PET scans (PSMA-PET) can better track how well treatment is working in men with metastatic hormone-sensitive prostate cancer. Twenty participants will receive standard care and undergo scans before and after 6 months of treatment. The goal is t…
Matched conditions: HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC